Aktionsplan Neuren Pharmaceuticals Limited
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. weitere details| Industry | Biotechnology |
|---|---|
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | aud |
| Сайт | https://www.neurenpharma.com |
| Цена ао | 10.33 |
| Preisänderung pro Tag: | 0% (7.868) |
|---|---|
| Preisänderung pro Woche: | 0% (7.868) |
| Preisänderung pro Monat: | -1.03% (7.95) |
| Preisänderung über 3 Monate: | -23.83% (10.33) |
| Preisänderung über sechs Monate: | -44.79% (14.25) |
| Preisänderung pro Jahr: | -53.66% (16.98) |
| Preisänderung über 3 Jahre: | +199.1% (2.6306) |
| Preisänderung über 5 Jahre: | +842.28% (0.835) |
| Preisänderung über 10 Jahre: | 0% (7.868) |
| Preisänderung seit Jahresbeginn: | -17.18% (9.5) |
|
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institutionen | Volumen | Aktie, % |
|---|---|---|
| Vanguard International Stock Index-Total Intl Stock Indx | 1480133 | 1.16 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 877162 | 0.69 |
| iShares Core MSCI EAFE ETF | 652944 | 0.51 |
| iShares MSCI EAFE Small Cap ETF | 436465 | 0.34 |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 403572 | 0.32 |
| Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 215442 | 0.17 |
| iShares Core MSCI Total International Stock ETF | 140892 | 0.11 |
| Vanguard International Stock Index-Pacific Stock Index | 128668 | 0.1 |
| College Retirement Equities Fund-Stock Account | 85378 | 0.07 |
| SEI Institutional International Tr-International Equity | 71485 | 0.06 |
| Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
|---|---|---|---|
| Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. | CEO, MD & Executive Director | 714.28k | |
| Ms. Lauren Frazer C.A. | CFO & Company Secretary | N/A | |
| Mr. Lawrence Glass BA (Biology) | Chief Science Officer | N/A | |
| Mr. Gerry Zhao | Vice President of Corporate Development | N/A | |
| Dr. Liza A. Squires M.D. | Chief Medical Officer | N/A |
Adresse: Australia, Camberwell, 697 Burke Road - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.neurenpharma.com
Webseite: https://www.neurenpharma.com
